Pulmonary surfactant

From WikiMD's WELLNESSPEDIA

A complex mixture of lipids and proteins that reduces surface tension in the lungs

Pulmonary Surfactant
Pulmonary surfactant.JPG
Synonyms N/A
Pronounce N/A
Specialty N/A
Symptoms N/A
Complications N/A
Onset N/A
Duration N/A
Types N/A
Causes N/A
Risks N/A
Diagnosis N/A
Differential diagnosis N/A
Prevention N/A
Treatment N/A
Medication N/A
Prognosis N/A
Frequency N/A
Deaths N/A


Pulmonary surfactant is a complex mixture of lipids and proteins that is secreted by the epithelial cells of the alveoli in the lungs. Its primary function is to reduce the surface tension at the air-liquid interface within the alveoli, preventing alveolar collapse and thereby maintaining proper lung function.

Structure and Composition[edit]

Pulmonary surfactant is composed of approximately 90% lipids and 10% proteins. The most abundant lipid is dipalmitoylphosphatidylcholine (DPPC), a phospholipid that plays a critical role in reducing surface tension. The protein component includes surfactant proteins A, B, C, and D, which are involved in surfactant metabolism and host defense.

Function[edit]

The primary function of pulmonary surfactant is to lower the surface tension of the fluid lining the alveoli. This reduction in surface tension prevents the alveoli from collapsing during exhalation and reduces the work of breathing. Surfactant also plays a role in innate immunity by binding to pathogens and facilitating their clearance by alveolar macrophages.

Synthesis and Secretion[edit]

Surfactant is synthesized and secreted by type II alveolar cells in the lungs. The synthesis of surfactant begins in the fetal lung around the 24th week of gestation, with significant production occurring by the 34th week. This timing is critical for the transition to air breathing at birth.

Clinical Significance[edit]

A deficiency in pulmonary surfactant can lead to respiratory distress syndrome (RDS), particularly in premature infants whose lungs have not yet produced adequate amounts of surfactant. Surfactant replacement therapy is a common treatment for neonatal RDS, involving the administration of exogenous surfactant to the infant's lungs.

Research and Developments[edit]

Ongoing research is focused on improving surfactant replacement therapies and understanding the role of surfactant in various lung diseases, including acute respiratory distress syndrome (ARDS) in adults.

Also see[edit]

Pulmonary surfactant[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.